Apolipoproteins AI and B as therapeutic targets

Area of Science:

• Biochemistry
• Cardiovascular Medicine
• Lipidology

Background:

• The apolipoprotein B:AI ratio is a superior predictor of cardiovascular disease (CVD) risk reduction compared to traditional lipid indices.
• Current CVD risk estimation relies on serum cholesterol and HDL cholesterol, which may be suboptimal.
• Apolipoprotein B (apo B) and apolipoprotein AI (apo AI) offer a more comprehensive assessment of lipoprotein metabolism and CVD risk.

Purpose of the Study:

• To evaluate the utility of the apolipoprotein B:AI ratio in assessing cardiovascular disease (CVD) risk.
• To explore the potential of using apolipoprotein B (apo B) as a therapeutic target for statin therapy.
• To determine the role of persistent hypertriglyceridaemia and HDL levels in guiding treatment efficacy.

Main Methods:

• Review of existing literature and meta-analyses on lipid and lipoprotein indices for CVD risk assessment.
• Analysis of randomized clinical trials reporting apolipoprotein B (apo B) and apolipoprotein AI (apo AI) levels.
• Comparative analysis of apo B:AI ratio against traditional lipid markers in predicting CVD risk reduction.

Main Results:

• The apolipoprotein B:AI ratio demonstrates superior performance in integrating CVD risk information compared to conventional lipid profiles.
• Targeting apolipoprotein B (apo B) for statin therapy may enhance treatment optimization and response assessment.
• Monitoring hypertriglyceridaemia is crucial for evaluating the reduction of small dense LDL particles, while raising HDL (apo AI) requires careful consideration of HDL function.

Conclusions:

• The apolipoprotein B:AI ratio should be considered for replacing serum cholesterol and HDL cholesterol in CVD risk estimation.
• Apolipoprotein B (apo B) offers a valuable target for optimizing statin therapy.
• Further meta-analyses of statin trials reporting apo B and apo AI are needed to fully elucidate their therapeutic implications.